The new facility, which is estimated to cost nearly €40 million, will be used, among other things, to expand production to serve new markets such as China. In the two - story building, which will be constructed on the current Allergopharma premises, products for the diagnosis and treatment of type 1 allergies.
ScinoPharm today announced that the company has completed construction of its Changshu plant on...
Roche and Prothena Corporation have entered into a worldwide collaboration to develop and...
The United States and 11 other nations negotiating a free trade zone stretching from Chile to Japan failed to reach a final agreement at talks in Singapore, but indicated they were closing in on a landmark deal.
Hong Kong reported its second human case of H7N9 bird flu just days after the first, raising fears that the virus is spreading beyond mainland China. The Health Department said late Friday that an 80-year-old man being treated for a chronic illness in the hospital was found to have the bird flu strain.
The European Medicines Agency has started an in-depth review of the benefits and risks of the leukemia medicine Iclusig, particularly the risk of blood clots or blockages in the arteries or veins that is associated with the medicine.
Genmab A/S announced today it had reached an in vivo pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a [Eur]1.5 million payment (approximately DKK 11 million).
AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorization to FluenzTM Tetra. Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age
Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.
Hong Kong is on public-health alert after the city confirmed its first human case of the deadly H7N9 bird flu.
Alvotech today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies. Alvotech’s current biosimilar assets include follow-on versions of leading monoclonal antibodies molecules, which will be brought to market by 2018.
Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion). Pharmaceutical and high-tech materials company Merck said Thursday that it will offer 403.5 pence ($6.61) in cash.
Our annual reader survey looks at issues facing innovator companies and the CMO/CSOs that support them.
As part of the realignment, Harvard Bioscience will reduce its global workforce by approximately 13 percent by eliminating certain operational redundancies across several sites, creating a leaner, more nimble organization. It plans to reinvest some of the savings into its China expansion, sales and marketing and product development initiatives, in order to drive growth.
JHL Biotech, Inc., a provider of biopharmaceutical process development and manufacturing services, and Switzerland-based Selexis SA, a provider of technologies for mammalian cell line development, announced today that they have signed a non-exclusive strategic agreement to provide biopharmaceutical customers a seamless solution for the development and cGMP manufacturing of biologic drugs.
Hong Kong has reported its first case of the H7N9 bird flu strain, in a possible sign the virus is spreading beyond mainland China since it first emerged there earlier this year. H7N9 was first identified April. It has sickened 139 people and killed 45 in China and Taiwan.
Who are the technical innovators in the US? The image we often have is that of the young Silicon Valley geek or the surfing California biopharma scientist -- sometimes brash and unafraid to challenge authority and champion new and better ideas.
GE Healthcare Life Sciences, and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech’s Research Center and manufacturing plant in Hsinchu, Taiwan. The new manufacturing platform will follow current good manufacturing practices (cGMP) and be fully operational by the end of 2013.
At least one person in Japan has been infected with HIV from a blood transfusion. A spokesman for the Japanese Red Cross Society said Tuesday that a male donor tested positive for HIV this month.
A French contraceptive maker says it will begin warning women that its morning-after pill is ineffective when taken by women who weigh more than 80 kilograms (176 pounds).
Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.
Mylan has announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer.
Swiss voters soundly rejected on Sunday a proposal to limit the pay of companies' highest-paid managers to 12 times that of their lowest-paid workers. Switzerland is home to global business players such as pharmaceutical companies Novartis and Roche; insurance groups Zurich and Swiss Re; and banks UBS and Credit Suisse.
Biopharm GmbH, Heidelberg, announced today that they have signed an agreement with Merck to cooperate with Merck Serono, the biopharmaceutical division of Merck in their research activities directed toward the molecular engineering of a biologic compound for the treatment of osteoarthritis.
The proposed legislation is part of a set of new proposals, outlined Tuesday, that are meant to address problems revealed by a series of catastrophic failures at the Stafford Hospital in central England, when hundreds of patients died unnecessarily from 2005 to 2009.
A Spanish court has ordered a German pharmaceutical company to pay compensation to 22 Spaniards born with disabilities after their mothers used the drug thalidomide during pregnancy decades ago.
The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.
Elan says its shareholders have approved the sale of the company to Perrigo Co. for $8.6 billion. The company said 99.5 percent of the shares voted at a special meeting were voted in favor of the sale. That made up 66 percent of its total shares. Perrigo reached a deal to buy Elan Corp. PLC in a cash and stock deal in July.
- Page 1